Page last updated: 2024-12-11

aldicarb sulfone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aldicarb sulfone: metabolite of aldicarb [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9570093
CHEMBL ID2138916
CHEBI ID82051
SCHEMBL ID23560
MeSH IDM0096613

Synonyms (67)

Synonym
unii-il70ans043
aldoxycarbe
il70ans043 ,
2-mesyl-2-methylpropionaldehyde o-methylcarbamoyloxime
2-methyl-2-(methylsulfonyl)propanal o-(methylcarbamoyl)oxime
aldoxycarb
2-methyl-2-(methylsulfonyl)propanal o-((methylamino)carbonyl)oxime
standak
epa pesticide chemical code 110801
aldoxycarb [ansi:bsi:iso]
propanal, 2-methyl-2-(methylsulfonyl)-, o-((methylamino)carbonyl)oxime
brn 1971375
2-methyl-2-methylsulphonylpropionaldehyde o-methylcarbamoyloxime
2-methyl-2-(methylsulphonyl)propionaldehyde o-(methylcarbamoyl)oxime
einecs 216-710-0
propionaldehyde, 2-methyl-2-(methylsulfonyl)-, o-(methylcarbamoyl)oxime
ai3-29261
propanal, 2-methyl-2-(methylsulfonyl)-, o-((methylamino)carbonyl) oxime
ent ai3-29261
sulfocarb
ent 4.9
uc-21865
aldoxycarbe [iso-french]
caswell no. 011aa
rcra waste no. p203
2-methyl-2-(methylsulfonyl)propionaldehyde o-(methylcarbamoyl)oxime
aldicarb sulfone
propanal, 2-methyl-2-(methylsulfonyl)-, o-[(methylamino)carbonyl]oxime
NCGC00160630-01
NCGC00160630-02
1646-88-4
2-methyl-2-(methylsulfonyl)propanal o-[(methylamino)carbonyl]oxime
NCGC00160630-03
C18906
cas-1646-88-4
dtxsid6023862 ,
NCGC00257229-01
tox21_303266
dtxcid503862
NCGC00258890-01
tox21_201338
uces
yangdimiewei
temik sulfone
aldicarb-sulfone
AKOS015912931
propanal, 2-methyl-2-(methylsulfonyl)-, o- ((methylamino)carbonyl) oxime
aldoxycarb [iso]
CS-3316
HY-17530
aldicarb (sulfone)
SCHEMBL23560
CHEBI:82051 ,
CHEMBL2138916
(1e)-2-methyl-1-(([(methylamino)carbonyl]oxy)imino)-2-(methylsulfonyl)propane #
carbamic acid, methyl-, o-[[2-methyl-2-(methylsulfonyl)propylidene]amino] deriv.
YRRKLBAKDXSTNC-WEVVVXLNSA-N
[(e)-(2-methyl-2-methylsulfonylpropylidene)amino] n-methylcarbamate
J-519547
aldicarb-sulfone, pestanal(r), analytical standard
J-010159
2-methyl-2-(methylsulfonyl)propanal-o-((methylamino)carbonyl)oxime
MS-23243
(e)-(2-methanesulfonyl-2-methylpropylidene)amino n- methylcarbamate
DTXSID50859666
aldicarb-d3sulfone
AKOS040759209

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
"In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency30.64850.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.80230.003041.611522,387.1992AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency4.84590.001530.607315,848.9004AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.42450.000229.305416,493.5996AID743069
aryl hydrocarbon receptorHomo sapiens (human)Potency68.86870.000723.06741,258.9301AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.37930.001723.839378.1014AID743083
heat shock protein beta-1Homo sapiens (human)Potency59.82530.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (31.58)18.7374
1990's6 (31.58)18.2507
2000's3 (15.79)29.6817
2010's4 (21.05)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.75 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]